B. Lactis B94 Effects of Gastrointestinal Function

Quality of Life Clinical Trial

Official title:

The Effects of Bifidobacterium Animalis Ssp. Lactis B94 on Gastrointestinal Function in Adults With Prader-Willi Syndrome: A Randomized, Double-blind Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03277157
• Other study ID #: IRB201701976
• Status: Completed
• Phase: N/A
• Start date: December 8, 2017
• Est. completion date: July 17, 2019

Study information

• Verified date: August 2019
• Source: University of Florida
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to determine the effect of daily consumption of Bifidobacterium animalis ssp lactis B94 (B. lactis B94) on stool frequency, gastrointestinal (GI) transit time, and gastrointestinal symptoms in adults with Prader-Willi syndrome. Participants (18-75 years old, n=36) will be recruited and enrolled in a 20-week randomized, placebo-controlled, crossover study. Study participants will be randomized to B. lactis B94 or placebo each for a 4-week period, preceded by a 4-week baseline and followed by 4-week washouts. Participants will complete daily questionnaires about stool frequency and stool form (transit). Dietary intake will also be assessed. A total of 5 stools (one in each period) will be collected for exploratory microbiota analysis. It is hypothesized that the B. lactis B94 will increase stool frequency, decrease the percentage of slow transit stools, and improve GI symptoms

Description:

Probiotics have been shown to improve symptoms of constipation by decreasing gastrointestinal transit time, increasing stool frequency, and normalizing stool form. A 20-week randomized, double-blinded, placebo-controlled crossover study will be carried out. Participants will complete a 4-week baseline period during which stool frequency, stool consistency (transit time), and gastrointestinal symptoms will be collected by paper questionnaire, and participants will collect a single stool. Dietary intake data (3-day) will be obtained during the baseline period. Participants will be randomized on or about day 29 and will consume Bifidobacterium animalis ssp lactis B94 (B. lactis B94) or placebo for 4 weeks, followed by a 4-week washout, 4 weeks on the alternative, and second 4-week washout. Participants will be randomized by sealed envelope method, prepared by a UF faculty member not affiliated with the study.

During the intervention and washout periods, participants will complete daily questionnaires to assess stool frequency and form (Bristol Stool Form Scale). Furthermore, they will complete Gastrointestinal Symptom Rating Scale (GSRS) at weeks 4, 8, 12, 16 and 20(± 3 days). During these same weeks (± 3 days) dietary intake data (28-day record) and stools will be collected (1 per period). Participants' height and weight will be taken at baseline, and weight during weeks 4, 8, 12, 16 and 20.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: July 17, 2019
• Est. primary completion date: October 31, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Are willing and able to provide informed consent.

• Have confirmed diagnosis of PWS

• Are willing to have height and weight measured and provide demographic information (e.g. age, race, sex)

• Are 18-75 years of age

• Are willing to consume B. lactis B94 and placebo each for 4-week periods

• Are willing to complete a daily questionnaire throughout the 20-week period.

• Are willing to complete the Gastrointestinal Symptom Rating Scale (GSRS) monthly throughout the 20-week study

• Are willing to provide information about their dietary intake for 3-days every 4 weeks

• Are willing to provide a valid social security for study payment purposes

Exclusion Criteria:

• Have a milk protein allergy

• Are currently taking medications for diarrhea

• Are currently taking probiotics supplements and do not want to discontinue prior to the start of the baseline period (i.e. those that discontinue will be included)

• Have previously or are currently being treated for any gastrointestinal diseases such as (gastric ulcers, Crohn's, Celiac, ulcerative colitis, etc.).

Related Conditions & MeSH terms

• Quality of Life

Intervention

Dietary Supplement:
• B. lactis B94
A probiotic dose of 15 billion per capsule.
• Placebo
Placebo capsule

Locations

Country	Name	City	State
United States	ARC of Alachua County	Gainesville	Florida
United States	Food Science and Human Nutrition Department, University of Florida	Gainesville	Florida
United States	UF Health Pediatrics - Gerold L. Schiebler CMS Center	Gainesville	Florida

Sponsors (2)

Lead Sponsor	Collaborator
University of Florida	Lallemand Health Solutions

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Stool frequency	Weekly stool frequency - difference between treatments	4 weeks
Secondary	Stool frequency percentage change	Weekly stool frequency: percentage change from baseline	4 weeks
Secondary	Bristol Stool Form	Percentage slow transit (Bristol Stool Form Scale 1 and 2)	4 weeks
Secondary	Gastrointestinal symptoms	Decrease in syndromes of Gastrointestinal Symptom Rating Scale (GSRS)	4 weeks
Secondary	Compliance	>80% of supplement intake	4 weeks